Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Document › Details

Glycotope GmbH. (1/7/16). "Press Release: Glycotope Names Paul G Higham as New Chief Executive Officer". Berlin.

Organisations Organisation Glycotope GmbH
  Group Glycotope (Group)
  Organisation 2 Immatics Biotechnologies GmbH
  Group Immatics (Group)
Products Product GlycoExpress™ cellular expression system (GEX™ technology)
  Product 2 glycosylation, protein
Persons Person Higham, Paul G. (Valo Therapeutics 202008– CEO before Glycotope + Immatics + Ark Therapeutics + GlaxoWellcome)
  Person 2 Goletz, Steffen (Glycotope 201601– CSO before since 200809 Managing Director + Founder)

Glycotope GmbH, a global leader in glyco-optimization of biopharmaceuticals, today announced the appointment of Paul G Higham as its new Chief Executive Officer (CEO), effective immediately.

“We are excited to further strengthen the Management Team of Glycotope through the appointment of Paul G Higham, a seasoned healthcare industry leader with extensive experience in the pharmaceutical and biotech sector. With his wealth of experience in the commercialization of therapeutics and his leadership of life science companies he is a perfect complement to lead Glycotope into the next phase of its development”, said Roland Sand, Chairman of the Board of Glycotope GmbH. “On behalf of the Board, I particularly would like to thank Dr. Steffen Goletz for his excellent support in selecting the right candidate for this key position. Over the past 15 years, Dr. Steffen Goletz successfully founded Glycotope and led the Company in his dual role as CEO and CSO into a well-financed mature biotech business with leading platforms, four products in advanced clinical development and over 200 employees. Going forward, he will, in his role as shareholder, board member and Chief Scientific Officer, increasingly focus on all scientific aspects that have made Glycotope the outstanding and innovative Company it is today.“

Paul G Higham, the new Chief Executive Officer of Glycotope GmbH, said: “I am delighted to join the leadership team of Glycotope at such an exciting time in the development of the Company. Glycotope has the potential to make a significant impact through its world-leading glycosylation technology platform. This has already enabled the Company to build a strong oncology clinical pipeline and the recent strategic alliance with Octapharma will also facilitate the creation of an innovative blood products capability.”

Paul G Higham was Chief Executive Officer of Immatics Biotechnologies from August 2008 to August 2015. During his time at the Company, Immatics grew and successfully developed into a leading cancer immunotherapy company with exceptional technologies, capabilities and growth opportunities. Previously, he served as Director Commercial Development at Ark Therapeutics Group plc where he was responsible for commercial strategy and all business development activities. In addition, he was in charge of establishing the operations and gene-based medicine production facilities of Ark Therapeutics in Finland. Before joining Ark Therapeutics in 2001, Paul G Higham worked as International Commercial Vice President for GI, Metabolic and Pain at GlaxoWellcome plc, where he was responsible for all aspects of international commercial strategy. Prior to that he held various sales and marketing positions with increasing responsibilities with Bayer AG becoming General Manager of Bayer Pharmaceuticals for Sweden and Denmark. He holds an honours degree in Applied Biology.

About Glycotope GmbH

Glycotope (, founded in 2001 in Berlin, focuses on the development of innovative immune-oncological products for the treatment of various cancer types using their GlycoBody™ and GlycoExpress™ technologies.

Glycotope´s GEX™ platform allows glyco-optimization of a variety of fully human glycosylated biopharmaceuticals such as coagulation factors, cytokines, glycoprotein hormones, antibodies, and other protein based biopharmaceuticals by using a toolbox of glyco-engineered proprietary human cell lines that allow for optimization of a whole series of different determining sugars. In addition, the GEX™ platform offers high yield production with unmet quality and reproducibility. Glycotope’s entire human blood coagulation business was recently partnered with Octapharma in an exclusive strategic deal in October 2015.

Record changed: 2016-01-10


Picture ConsulTech GmbH GDPR-compliant E-Col Cloud Document Management 650x80px

More documents for Glycotope (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioTech Showcase 2021 Whitepaper Presenting 650x80

» top